French biotech firm surprises analysts with corona vaccine data

French biotech company Valneva has surprised the market with positive Covid-19 vaccine data, something one analyst welcomes, as different types of boosters may be necessary in the ongoing fight against the virus.
Photo: David Vincent/AP/Ritzau Scanpix
Photo: David Vincent/AP/Ritzau Scanpix
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

After a rollercoaster year, French biotech business Valneva is experiencing somewhat of a comeback on the Covid-19 front, after having presented promising phase III data for its Covid-19 vaccine. Investors have rewarded it by sending Valneva stock up by more than 30 percent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading